dexamethasone, procarbazine

PreclinicalSmall molecule

dexamethasone, procarbazine is one of 7 small molecule programs targeting Ataxia-telangiectasia. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Ataxia-TelangiectasiaActive, not recruiting

Ataxia-TelangiectasiaPreclinical

Active, not recruiting

Competition

Competitive Landscape

8 competitors in Ataxia-Telangiectasia

#DrugCompanyPhaseTrials

Actos

Takeda

Approved

1 2

Glucophage

EMD Serono

Approved

1 3

N-Acetyl-L-Leucine

IIntraBio Inc

Phase 3

1 4

Nicotinamide Riboside

UUniversity of Oklahoma

Preclinical

1 5

Prevenar

GSK

Preclinical

1 6

dexamethasone, procarbazine

SSt. Jude Children's Research Hospital

Preclinical

1 7

Pneumovax

NNational Institute of Allergy and Infectious Diseases (NIAID)

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Ataxia-telangiectasia1 trial

Study for Treatment of Cancer in Children With Ataxia-telangiectasia

Completed·SSt. Jude Children's Research Hospital·N/A·NCT00187057·6 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for dexamethasone, procarbazine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — dexamethasone, procarbazine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for dexamethasone, procarbazine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — St. Jude Children's Research Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: SSt. Jude Children's Research Hospital

dexamethasone, procarbazine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Ataxia-telangiectasia1 trial

References

Drug Info

Quick Facts

Related News